分子標的薬であるスニチニブの関与が疑われた長期間骨露出を呈した抜歯窩治癒不全の1例

• Published in: 日本口腔外科学会雑誌 Vol. 60; no. 8; pp. 494 - 498
• Main Authors: 箭原, 元基, 鈴木, 豊典, 鄭, 漢忠, 松田, 光平, 格口, 渉, 藤田, 温志
• Format: Journal Article
• Language: Japanese
• Published: 社団法人 日本口腔外科学会 20.08.2014
• Subjects: スニチニブ; 血管内皮増殖因子; 血管新生阻害; 顎骨壊死; 骨露出
• ISSN: 0021-5163; 2186-1579
• DOI: 10.5794/jjoms.60.494

Sunitinib, a multitargeted tyrosine kinase inhibitor that inhibits angiogenesis, improves progressionfree survival in advanced renal cell carcinoma, gastrointestinal stromal tumor, and pancreatic neuroendocrine tumor. Sunitinib triggers wound healing failure and osteonecrosis of the jaw because it inhibits not only angiogenesis, but also the functions of osteoblasts and osteoclasts. A 51-year-old man with a diagnosis of intraabdominal gastrointestinal stromal tumor was treated with sunitinib. He had his teeth extracted from the right and left sides of the upper jaw by a dental practitioner on the first day of the second cycle of sunitinib. He was referred to our hospital because of bone exposure in the sockets 26 days after teeth extraction. Examination revealed bone exposure in the right and left sides of the upper jaw. The patient had had no history of bisphosphonate or radiation therapy. During continuous treatment with sunitinib, he was followed up with washing the sockets and the mouth. The sockets were epithelialized within 105 days after teeth extraction. Our findings suggest that patients treated with sunitinib should be closely observed for wound healing failure after surgical treatment.